Trial | NCT00467935  Report issue

Title

Scotoma Reduction in AMD Patients Treated With Ranibizumab
A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    ranibizumab ...

  • Study Participants

    20
This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.
Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.
Study Started
Mar 31
2007
Primary Completion
Nov 30
2007
Study Completion
Nov 30
2007
Last Update
Jul 29
2011
Estimate

Drug intravitreal injection Lucentis (ranibizumab)

intravitreal injection Lucentis (ranibizumab)

Criteria 

Inclusion Criteria:

BCVA < 20/320
Disciform macular degeneration wiht exudation

Exclusion Criteria:

Non-amd CNV
No Results Posted